Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Response rates ranged from 56% to 85% for several types of tumors with high HER2 expression.
This treatment represents a “fairly substantial breakthrough” for patients with HER2-positive advanced colorectal cancer.
Research also showed that treatment before surgery benefits patients with HER2-low breast cancer.
The antibody-drug conjugate improved progression-free and overall survival for patients with low HER2 expression on breast tumors.
The antibody-drug conjugate improved response rates and survival compared with chemotherapy.
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.
New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.